



EUROPEAN COMMISSION  
DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY  
Health systems, medical products and innovation  
Medicines: policy, authorisation and monitoring

Brussels,  
SANTÉ/B5/ (2017)ddg1.b5.

## Minutes of the meeting Meeting with EuropaBio VP Chair

Participants: EuropaBio: (Senior Vice President); (Director Healthcare Biotechnology);

DG SANTE: M. Seychell (MS); (B4), (B5)

They expressed concerns about the study on incentives to be carried out by the Commission following the Council conclusions. They stressed that pharmaceutical spending represents about 10% of total health expenditure and therefore sustainability of health systems depends more on other factors. EuropaBio therefore considers that the study should not make the wrong link between sustainability of health systems and pharmaceutical incentives, but examine this topic in a the wider context. They claimed that review of incentives could impact negatively biotech innovation in Europe and that certain messages could bridge the trust of patients and society to pharmaceutical companies. They also raised concerns as regards review of the incentives for paediatric medicines.

MS explained that the study will analyse the impact of incentives not only on affordability and accessibility but also on innovation. It was stressed that the study will not put in question the need for incentives as such but will examine whether the incentives have achieved their objective. MS stressed that the study will be factual and address all issues in a holistic way. COM will then assess the totality of the evidence before taking any decision for next steps with regard to reviewing the incentives. In any case better regulation rules, including evaluation, impact assessment and consultation apply. As regards paediatrics, COM informed that the study on economic impact of the regulation is completed and the report will be ready this year. MS invited EuropaBio to contribute to the study on incentives, as input from of industry will be essential in keeping the study informed and balanced.

EuropaBio confirmed that both them and EFPIA are willing to be involved in the study.